<a id='838a347a-31b2-42b0-b637-fcd9b84c4bb8'></a>

Balance Sheet as at 31st March, 2025

<a id='5fbafd15-6fb6-43ea-9a24-8728f584dcb6'></a>

<table id="0-1">
<tr><td id="0-2"></td><td id="0-3">Notes</td><td id="0-4">As at 31st March, 2025</td><td id="0-5">As at 31st March, 2024</td></tr>
<tr><td id="0-6"></td><td id="0-7"></td><td id="0-8">(in ₹ million)</td><td id="0-9">(in ₹ million)</td></tr>
<tr><td id="0-a" colspan="4">Assets</td></tr>
<tr><td id="0-b" colspan="4">Non-Current Assets</td></tr>
<tr><td id="0-c">Property, Plant and Equipment</td><td id="0-d">2</td><td id="0-e">9.7</td><td id="0-f">16.5</td></tr>
<tr><td id="0-g">Right-of-Use Assets</td><td id="0-h">31</td><td id="0-i">35.7</td><td id="0-j">52.9</td></tr>
<tr><td id="0-k">Financial Assets</td><td id="0-l"></td><td id="0-m"></td><td id="0-n"></td></tr>
<tr><td id="0-o">(i) Other Financial Assets</td><td id="0-p">3</td><td id="0-q">10.6</td><td id="0-r">21.7</td></tr>
<tr><td id="0-s">Deferred Tax Assets (Net)</td><td id="0-t">4</td><td id="0-u">154.8</td><td id="0-v">153.7</td></tr>
<tr><td id="0-w">Other Tax Assets (Net)</td><td id="0-x">5</td><td id="0-y">1,152.5</td><td id="0-z">1,232.0</td></tr>
<tr><td id="0-A">Other Non-Current Assets</td><td id="0-B">6</td><td id="0-C">656.6</td><td id="0-D">779.9</td></tr>
<tr><td id="0-E">Total Non-Current assets</td><td id="0-F"></td><td id="0-G">2,019.9</td><td id="0-H">2,256.8</td></tr>
<tr><td id="0-I" colspan="4">Current Assets</td></tr>
<tr><td id="0-J">Inventories</td><td id="0-K">7</td><td id="0-L">411.1</td><td id="0-M">448.6</td></tr>
<tr><td id="0-N">Financial Assets</td><td id="0-O"></td><td id="0-P"></td><td id="0-Q"></td></tr>
<tr><td id="0-R">(i) Trade Receivables</td><td id="0-S">8</td><td id="0-T">401.4</td><td id="0-U">414.7</td></tr>
<tr><td id="0-V">(ii) Cash and Cash Equivalents</td><td id="0-W">9(a)</td><td id="0-X">520.7</td><td id="0-Y">449.8</td></tr>
<tr><td id="0-Z">(iii) Bank Balances other than (ii) above</td><td id="0-10">9(b)</td><td id="0-11">5,959.6</td><td id="0-12">5,511.0</td></tr>
<tr><td id="0-13">(iv) Other Financial Assets</td><td id="0-14">3</td><td id="0-15">9.4</td><td id="0-16">8.1</td></tr>
<tr><td id="0-17">Other Current Assets</td><td id="0-18">10</td><td id="0-19">156.0</td><td id="0-1a">160.4</td></tr>
<tr><td id="0-1b">Total Current assets</td><td id="0-1c"></td><td id="0-1d">7,458.2</td><td id="0-1e">6,992.6</td></tr>
<tr><td id="0-1f">Total Assets</td><td id="0-1g"></td><td id="0-1h">9,478.1</td><td id="0-1i">9,249.3</td></tr>
<tr><td id="0-1j" colspan="4">Equity and Liabilities</td></tr>
<tr><td id="0-1k">Equity</td><td id="0-1l"></td><td id="0-1m"></td><td id="0-1n"></td></tr>
<tr><td id="0-1o">Equity Share Capital</td><td id="0-1p">11</td><td id="0-1q">123.4</td><td id="0-1r">123.4</td></tr>
<tr><td id="0-1s">Other Equity</td><td id="0-1t">12</td><td id="0-1u">7,726.2</td><td id="0-1v">7,324.8</td></tr>
<tr><td id="0-1w">Total Equity</td><td id="0-1x"></td><td id="0-1y">7,849.6</td><td id="0-1z">7,448.2</td></tr>
<tr><td id="0-1A" colspan="4">Liabilities</td></tr>
<tr><td id="0-1B" colspan="4">Non-Current Liabilities</td></tr>
<tr><td id="0-1C">Financial Liabilities</td><td id="0-1D"></td><td id="0-1E"></td><td id="0-1F"></td></tr>
<tr><td id="0-1G">(i) Lease Liabilities</td><td id="0-1H">31</td><td id="0-1I">32.1</td><td id="0-1J">50.7</td></tr>
<tr><td id="0-1K">(i) Other Financial Liabilities</td><td id="0-1L">13(b)</td><td id="0-1M">2.0</td><td id="0-1N">2.2</td></tr>
<tr><td id="0-1O">Provisions</td><td id="0-1P">14</td><td id="0-1Q">173.9</td><td id="0-1R">176.2</td></tr>
<tr><td id="0-1S">Total Non-Current Liabilities</td><td id="0-1T"></td><td id="0-1U">208.0</td><td id="0-1V">229.1</td></tr>
<tr><td id="0-1W" colspan="4">Current Liabilities</td></tr>
<tr><td id="0-1X" colspan="4">Financial Liabilities</td></tr>
<tr><td id="0-1Y">(i) Borrowings</td><td id="0-1Z">13(a)</td><td id="0-20">–</td><td id="0-21">0.2</td></tr>
<tr><td id="0-22">(ii) Lease Liabilities</td><td id="0-23">31</td><td id="0-24">18.5</td><td id="0-25">18.8</td></tr>
<tr><td id="0-26">(iii) Trade Payables</td><td id="0-27"></td><td id="0-28"></td><td id="0-29"></td></tr>
<tr><td id="0-2a">– total outstanding dues of micro and small enterprises</td><td id="0-2b">13(c)</td><td id="0-2c">4.5</td><td id="0-2d">6.4</td></tr>
<tr><td id="0-2e">– total outstanding dues of creditors other than micro and small enterprises</td><td id="0-2f">13(c)</td><td id="0-2g">510.2</td><td id="0-2h">609.5</td></tr>
<tr><td id="0-2i">(iv) Other Financial Liabilities</td><td id="0-2j">13(b)</td><td id="0-2k">195.4</td><td id="0-2l">266.2</td></tr>
<tr><td id="0-2m">Other Current Liabilities</td><td id="0-2n">15</td><td id="0-2o">34.4</td><td id="0-2p">50.4</td></tr>
<tr><td id="0-2q">Provisions</td><td id="0-2r">14</td><td id="0-2s">523.1</td><td id="0-2t">545.7</td></tr>
<tr><td id="0-2u">Current Tax Liabilities (Net)</td><td id="0-2v">16</td><td id="0-2w">134.4</td><td id="0-2x">74.8</td></tr>
<tr><td id="0-2y">Total Current Liabilities</td><td id="0-2z"></td><td id="0-2A">1,420.5</td><td id="0-2B">1,572.0</td></tr>
<tr><td id="0-2C">Total Equity and Liabilities</td><td id="0-2D"></td><td id="0-2E">9,478.1</td><td id="0-2F">9,249.3</td></tr>
</table>

<a id='f7783ed6-af0f-4531-9d28-3953bf6f68a3'></a>

The above balance sheet should be read in conjunction with the accompanying notes.
As per our report of even date attached.

For B S R & Co. LLP
Chartered Accountants
Firm's Registration Number – 101248W/W – 100022

For and on behalf of Novartis India Limited
CIN – L24200MH1947PLC006104

Christopher Snook
Chairman
DIN: 00369790

Shilpa Joshi
Whole time Director &
Chief Financial Officer
DIN: 09775615

<a id='be92ccf3-4d53-4060-9b4b-21ca467cbabd'></a>

Maulik Jhaveri
Partner
Membership no. 116008
Mumbai, 9 May, 2025

Chandni Maru
Company Secretary & Compliance Officer
Membership no. ACS 60291
Mumbai, 9 May, 2025

<a id='f16135c9-5cfc-485e-84c3-8c9979381b92'></a>

126

<a id='d546a06d-ab29-43e2-8806-2f03b7b8e9d6'></a>

NOVARTIS INDIA LIMITED
Annual Report 2024–25

<!-- PAGE BREAK -->

<a id='088b5a13-d342-4a2d-a6ed-9218b919d561'></a>

Statement of Profit and Loss for the year ended 31st March, 2025

<a id='f0661adf-a61e-47c5-85f7-5c0e3c76d359'></a>

<table id="1-1">
<tr><td id="1-2"></td><td id="1-3">Notes</td><td id="1-4">Year ended 31st March, 2025</td><td id="1-5">Year ended 31st March, 2024</td></tr>
<tr><td id="1-6"></td><td id="1-7"></td><td id="1-8">(in ₹ million)</td><td id="1-9">(in ₹ million)</td></tr>
<tr><td id="1-a" colspan="4">Income</td></tr>
<tr><td id="1-b">Revenue from Operations</td><td id="1-c">17</td><td id="1-d">3,562.7</td><td id="1-e">3,350.7</td></tr>
<tr><td id="1-f">Other Income</td><td id="1-g">18</td><td id="1-h">419.6</td><td id="1-i">616.8</td></tr>
<tr><td id="1-j">Total Income</td><td id="1-k"></td><td id="1-l">3,982.3</td><td id="1-m">3,967.5</td></tr>
<tr><td id="1-n" colspan="4">Expenses</td></tr>
<tr><td id="1-o">Purchases of Stock-in-Trade</td><td id="1-p"></td><td id="1-q">1,990.7</td><td id="1-r">1,899.8</td></tr>
<tr><td id="1-s">Changes in Inventories of Stock-in-Trade</td><td id="1-t">19</td><td id="1-u">37.5</td><td id="1-v">98.6</td></tr>
<tr><td id="1-w">Employee Benefits Expense</td><td id="1-x">20</td><td id="1-y">187.2</td><td id="1-z">229.6</td></tr>
<tr><td id="1-A">Finance Costs</td><td id="1-B">21</td><td id="1-C">7.7</td><td id="1-D">14.9</td></tr>
<tr><td id="1-E">Depreciation Expense</td><td id="1-F">22</td><td id="1-G">21.9</td><td id="1-H">26.1</td></tr>
<tr><td id="1-I">Impairment loss on receivables</td><td id="1-J"></td><td id="1-K">(1.7)</td><td id="1-L">1.7</td></tr>
<tr><td id="1-M">Other Expenses</td><td id="1-N">23(a)</td><td id="1-O">434.8</td><td id="1-P">468.4</td></tr>
<tr><td id="1-Q">Total Expenses</td><td id="1-R"></td><td id="1-S">2,678.1</td><td id="1-T">2,739.1</td></tr>
<tr><td id="1-U">Profit before Tax</td><td id="1-V"></td><td id="1-W">1,304.2</td><td id="1-X">1,228.4</td></tr>
<tr><td id="1-Y">Tax Expense</td><td id="1-Z">27</td><td id="1-10"></td><td id="1-11"></td></tr>
<tr><td id="1-12">Current Tax</td><td id="1-13"></td><td id="1-14">299.6</td><td id="1-15">376.3</td></tr>
<tr><td id="1-16">Deferred Tax</td><td id="1-17"></td><td id="1-18">(4.4)</td><td id="1-19">0.2</td></tr>
<tr><td id="1-1a">Total Tax Expense</td><td id="1-1b"></td><td id="1-1c">295.2</td><td id="1-1d">376.5</td></tr>
<tr><td id="1-1e">Profit for the year</td><td id="1-1f"></td><td id="1-1g">1,009.0</td><td id="1-1h">851.9</td></tr>
<tr><td id="1-1i" colspan="4">Other Comprehensive Income</td></tr>
<tr><td id="1-1j" colspan="3">Items that will not be reclassified to profit or loss</td><td id="1-1k"></td></tr>
<tr><td id="1-1l">Remeasurements gain on Defined Benefit Plans</td><td id="1-1m"></td><td id="1-1n">13.0</td><td id="1-1o">16.2</td></tr>
<tr><td id="1-1p">Income tax relating to these items</td><td id="1-1q"></td><td id="1-1r">(3.3)</td><td id="1-1s">(4.1)</td></tr>
<tr><td id="1-1t">Other Comprehensive Income for the year</td><td id="1-1u"></td><td id="1-1v">9.7</td><td id="1-1w">12.1</td></tr>
<tr><td id="1-1x">Total Comprehensive Income for the year</td><td id="1-1y"></td><td id="1-1z">1,018.7</td><td id="1-1A">864.0</td></tr>
<tr><td id="1-1B">Earnings per Share – Basic and Diluted [per Equity Share of ₹ 5 each]</td><td id="1-1C">32</td><td id="1-1D">40.87</td><td id="1-1E">34.50</td></tr>
</table>

<a id='7378d36a-261e-44e8-9ad4-8a8837ebacff'></a>

The above Statement of Profit and Loss should be read in conjunction with the accompanying notes.
As per our report of even date attached.                          For and on behalf of Novartis India Limited
                                                                  CIN – L24200MH1947PLC006104

<a id='18292d59-d41c-4d68-8db4-26b40e152533'></a>

For B S R & Co. LLP
Chartered Accountants
Firm's Registration Number - 101248W/W-100022

<a id='285a9fbe-f3af-4a6a-af32-b6a5201bda1f'></a>

Christopher Snook
Chairman
DIN: 00369790

<a id='06ed2a2d-6ed7-4e9a-acf4-2016dd964cd4'></a>

**Shilpa Joshi**
*Whole time Director &
Chief Financial Officer*
DIN: 09775615

<a id='5c5ef63c-8f51-49f4-a213-9dcc22cedb5a'></a>

**Maulik Jhaveri**
*Partner*
Membership no. 116008
Mumbai, 9 May, 2025

<a id='e9d5369d-0985-4550-a63f-0176f80587ee'></a>

Chandni Maru
Company Secretary & Compliance Officer
Membership no. ACS 60291
Mumbai, 9 May, 2025

<a id='fed8ddd6-d118-4878-942a-ff08ea6e7e8c'></a>

NOVARTIS INDIA LIMITEDAnnual Report 2024–25

<a id='01ae9cd0-da9b-4526-95e5-a20229e575fa'></a>

127

<!-- PAGE BREAK -->

<a id='2cc344f0-1774-40fd-8ca0-d5d2fbcec949'></a>

Statement of Changes in Equity for the year ended 31st March, 2025

<a id='7e4e2c5e-0694-4263-a20f-70900eb17222'></a>

A. Equity Share Capital
<table id="2-1">
<tr><td id="2-2"></td><td id="2-3">Note 11</td><td id="2-4">Amount (in ₹ million)</td></tr>
<tr><td id="2-5">Balance as at 1st April, 2024</td><td id="2-6"></td><td id="2-7">123.4</td></tr>
<tr><td id="2-8">Change in Equity Share Capital due to prior period errors</td><td id="2-9"></td><td id="2-a">—</td></tr>
<tr><td id="2-b">Change in Equity Share Capital during the year</td><td id="2-c"></td><td id="2-d">—</td></tr>
<tr><td id="2-e">Balance as at 31st March, 2025</td><td id="2-f"></td><td id="2-g">123.4</td></tr>
<tr><td id="2-h">Balance as at 1st April, 2023</td><td id="2-i"></td><td id="2-j">123.4</td></tr>
<tr><td id="2-k">Change in Equity Share Capital due to prior period errors</td><td id="2-l"></td><td id="2-m">–</td></tr>
<tr><td id="2-n">Change in Equity Share Capital during the year</td><td id="2-o"></td><td id="2-p">–</td></tr>
<tr><td id="2-q">Balance as at 31st March, 2024</td><td id="2-r"></td><td id="2-s">123.4</td></tr>
</table>

<a id='c18d8f55-c53a-41da-a6ca-9171e006c923'></a>

<table id="2-t">
<tr><td id="2-u">B. Other Equity</td><td id="2-v" colspan="5">Attributable to the equity holders of the Company (in ₹ million)</td></tr>
<tr><td id="2-w"></td><td id="2-x" colspan="5">Reserves and Surplus</td></tr>
<tr><td id="2-y"></td><td id="2-z">Note 12</td><td id="2-A">Capital Redemption Reserve</td><td id="2-B">Share Options Outstanding Account</td><td id="2-C">Retained Earnings</td><td id="2-D">Total Other Equity</td></tr>
<tr><td id="2-E">Balance as at 1st April, 2024</td><td id="2-F"></td><td id="2-G">36.4</td><td id="2-H">–</td><td id="2-I">7,288.4</td><td id="2-J">7,324.8</td></tr>
<tr><td id="2-K">Profit for the year</td><td id="2-L"></td><td id="2-M">–</td><td id="2-N">–</td><td id="2-O">1,009.0</td><td id="2-P">1,009.0</td></tr>
<tr><td id="2-Q">Other Comprehensive Income for the year Remeasurement gain on defined benefit plans net of tax</td><td id="2-R"></td><td id="2-S">—</td><td id="2-T">—</td><td id="2-U">9.7</td><td id="2-V">9.7</td></tr>
<tr><td id="2-W">Total Comprehensive Income for the year</td><td id="2-X"></td><td id="2-Y">—</td><td id="2-Z">—</td><td id="2-10">1,018.7</td><td id="2-11">1,018.7</td></tr>
<tr><td id="2-12" colspan="6">Distribution to Owners</td></tr>
<tr><td id="2-13">Dividends</td><td id="2-14"></td><td id="2-15">—</td><td id="2-16">—</td><td id="2-17">(617.3)</td><td id="2-18">(617.3)</td></tr>
<tr><td id="2-19">Balance as at 31st March, 2025</td><td id="2-1a"></td><td id="2-1b">36.4</td><td id="2-1c">—</td><td id="2-1d">7,689.8</td><td id="2-1e">7,726.2</td></tr>
<tr><td id="2-1f">Balance as at 1st April, 2023</td><td id="2-1g"></td><td id="2-1h">36.4</td><td id="2-1i">(0.4)</td><td id="2-1j">7,597.2</td><td id="2-1k">7,633.2</td></tr>
<tr><td id="2-1l">Profit for the year</td><td id="2-1m"></td><td id="2-1n">—</td><td id="2-1o">—</td><td id="2-1p">851.9</td><td id="2-1q">851.9</td></tr>
<tr><td id="2-1r">Other Comprehensive Income for the year Remeasurement gain on defined benefit plans net of tax</td><td id="2-1s"></td><td id="2-1t">—</td><td id="2-1u">—</td><td id="2-1v">12.1</td><td id="2-1w">12.1</td></tr>
<tr><td id="2-1x">Total Comprehensive Income for the year</td><td id="2-1y"></td><td id="2-1z">—</td><td id="2-1A">—</td><td id="2-1B">864.0</td><td id="2-1C">864.0</td></tr>
<tr><td id="2-1D" colspan="6">Transactions with owners of the Company</td></tr>
<tr><td id="2-1E" colspan="6">Distribution to Owners</td></tr>
<tr><td id="2-1F">Dividends</td><td id="2-1G"></td><td id="2-1H">—</td><td id="2-1I">—</td><td id="2-1J">(1,172.8)</td><td id="2-1K">(1,172.8)</td></tr>
<tr><td id="2-1L">Expense charged to Statement of Profit and Loss (net) [Refer Note 20]</td><td id="2-1M"></td><td id="2-1N">—</td><td id="2-1O">0.4</td><td id="2-1P">—</td><td id="2-1Q">0.4</td></tr>
<tr><td id="2-1R">Balance as at 31st March, 2024</td><td id="2-1S"></td><td id="2-1T">36.4</td><td id="2-1U">—</td><td id="2-1V">7,288.4</td><td id="2-1W">7,324.8</td></tr>
</table>

<a id='a585f01f-31b7-4156-a21f-a3cc9a896d88'></a>

The above Statement of Changes in Equity should be read in conjunction with the accompanying notes.
As per our report of even date attached.
For and on behalf of Novartis India Limited
CIN - 124200MH1947PLC006104

<a id='15d569a4-a0e0-4e62-88d9-f80f02789905'></a>

For B S R & Co. LLP
Chartered Accountants
Firm's Registration Number - 101248W/W-100022

<a id='89ce5ee2-4c98-4a88-88d9-c462243494af'></a>

Christopher Snook
Chairman
DIN: 00369790

<a id='acdbb9fc-9395-4bf6-965c-edc4a0974fa1'></a>

Shilpa Joshi
Whole time Director &
Chief Financial Officer
DIN: 09775615

<a id='3a2c63b9-3e94-4144-8b49-d6d0e65573f3'></a>

**Maulik Jhaveri**
*Partner*
Membership no. 116008
Mumbai, 9 May, 2025

<a id='cb4dd63e-cbe2-4ab6-83ae-bb699e0255d4'></a>

Chandni Maru
Company Secretary & Compliance Officer
Membership no. ACS 60291
Mumbai, 9 May, 2025

<a id='0e1ed105-2669-499d-bf64-8c0416ce04e1'></a>

128

<a id='b2c66488-4d3c-40fc-92b2-1fd04c4eb5db'></a>

NOVARTIS INDIA LIMITED
Annual Report 2024–25

<!-- PAGE BREAK -->

<a id='f329cf31-4657-4c73-aaba-11f21884145c'></a>

Statement of Cash Flows for the period ended 31st March, 2025

<a id='2128431e-4f43-4e1c-ba73-76b686ee86b0'></a>

<table id="3-1">
<tr><td id="3-2"></td><td id="3-3"></td><td id="3-4">Year ended 31st March, 2025</td><td id="3-5">Year ended 31st March, 2024</td></tr>
<tr><td id="3-6"></td><td id="3-7"></td><td id="3-8">(in ₹ million)</td><td id="3-9">(in ₹ million)</td></tr>
<tr><td id="3-a">A.</td><td id="3-b" colspan="3">Cash flow from operating activities</td></tr>
<tr><td id="3-c"></td><td id="3-d">Profit before tax</td><td id="3-e">1,304.2</td><td id="3-f">1,228.4</td></tr>
<tr><td id="3-g"></td><td id="3-h" colspan="3">Adjustments for -</td></tr>
<tr><td id="3-i"></td><td id="3-j">Depreciation Expense</td><td id="3-k">21.9</td><td id="3-l">26.1</td></tr>
<tr><td id="3-m"></td><td id="3-n">Share Based Payments</td><td id="3-o">3.3</td><td id="3-p">2.5</td></tr>
<tr><td id="3-q"></td><td id="3-r">(Gain) on Sale/Disposal of Asset held for sale</td><td id="3-s">–</td><td id="3-t">(32.1)</td></tr>
<tr><td id="3-u"></td><td id="3-v">Interest Income</td><td id="3-w">(408.8)</td><td id="3-x">(51.9)</td></tr>
<tr><td id="3-y"></td><td id="3-z">Unwinding of discount on security deposits</td><td id="3-A">(0.7)</td><td id="3-B">(1.5)</td></tr>
<tr><td id="3-C"></td><td id="3-D">Finance Costs</td><td id="3-E">7.7</td><td id="3-F">14.9</td></tr>
<tr><td id="3-G"></td><td id="3-H">(Gain) on derecognition of lease liability and Right-of-Use Assets</td><td id="3-I">—</td><td id="3-J">(26.8)</td></tr>
<tr><td id="3-K"></td><td id="3-L">(Gain) on sale of Property, Plant and Equipment (Net)</td><td id="3-M">(1.1)</td><td id="3-N">—</td></tr>
<tr><td id="3-O"></td><td id="3-P">Unrealised (gain)/loss on Foreign currency transactions (Net)</td><td id="3-Q">(3.2)</td><td id="3-R">1.0</td></tr>
<tr><td id="3-S"></td><td id="3-T">Credit Balances Written-Back</td><td id="3-U">(5.5)</td><td id="3-V">(4.5)</td></tr>
<tr><td id="3-W"></td><td id="3-X">Impairment loss on receivables</td><td id="3-Y">(1.7)</td><td id="3-Z">1.7</td></tr>
<tr><td id="3-10"></td><td id="3-11">Provision for deposits/advances (net)</td><td id="3-12">0.1</td><td id="3-13">3.1</td></tr>
<tr><td id="3-14"></td><td id="3-15">Operating cash flows before working capital changes</td><td id="3-16">916.2</td><td id="3-17">660.9</td></tr>
<tr><td id="3-18"></td><td id="3-19" colspan="3">Working Capital Adjustment</td></tr>
<tr><td id="3-1a"></td><td id="3-1b">Decrease/(Increase) Trade Receivables</td><td id="3-1c">15.0</td><td id="3-1d">(53.4)</td></tr>
<tr><td id="3-1e"></td><td id="3-1f">Decrease Inventories</td><td id="3-1g">37.5</td><td id="3-1h">98.6</td></tr>
<tr><td id="3-1i"></td><td id="3-1j">Decrease Non-current Financial Assets Others</td><td id="3-1k">10.8</td><td id="3-1l">1.5</td></tr>
<tr><td id="3-1m"></td><td id="3-1n">Decrease Current Financial Assets Others</td><td id="3-1o">(1.1)</td><td id="3-1p">57.9</td></tr>
<tr><td id="3-1q"></td><td id="3-1r">Decrease Other Non-Current Assets</td><td id="3-1s">123.3</td><td id="3-1t">111.1</td></tr>
<tr><td id="3-1u"></td><td id="3-1v">(Increase) Other Current Assets</td><td id="3-1w">1.1</td><td id="3-1x">(0.8)</td></tr>
<tr><td id="3-1y"></td><td id="3-1z">(Decrease)/Increase Trade Payables</td><td id="3-1A">(92.5)</td><td id="3-1B">21.2</td></tr>
<tr><td id="3-1C"></td><td id="3-1D">(Decrease) Provisions</td><td id="3-1E">(11.9)</td><td id="3-1F">(45.1)</td></tr>
<tr><td id="3-1G"></td><td id="3-1H">(Decrease)/Increase Other Current Liabilities</td><td id="3-1I">(16.0)</td><td id="3-1J">12.6</td></tr>
<tr><td id="3-1K"></td><td id="3-1L">(Decrease) Non-current Financial Liabilities</td><td id="3-1M">(0.2)</td><td id="3-1N">(75.6)</td></tr>
<tr><td id="3-1O"></td><td id="3-1P">(Decrease) Current Financial Liabilities</td><td id="3-1Q">(73.6)</td><td id="3-1R">(37.6)</td></tr>
<tr><td id="3-1S"></td><td id="3-1T">Cash generated from operations</td><td id="3-1U">908.6</td><td id="3-1V">751.3</td></tr>
<tr><td id="3-1W"></td><td id="3-1X">Income Tax (Paid)/Refund received</td><td id="3-1Y">(162.9)</td><td id="3-1Z">382.7</td></tr>
<tr><td id="3-20"></td><td id="3-21">Net Cash generated from operating activities</td><td id="3-22">745.7</td><td id="3-23">1,134.0</td></tr>
<tr><td id="3-24">B.</td><td id="3-25" colspan="3">Cash flow from investing activities</td></tr>
<tr><td id="3-26"></td><td id="3-27">Proceeds from disposal of Property, Plant and Equipment</td><td id="3-28">3.2</td><td id="3-29"></td></tr>
<tr><td id="3-2a"></td><td id="3-2b">Proceeds from disposal of Asset Held for Sale</td><td id="3-2c">—</td><td id="3-2d">32.7</td></tr>
<tr><td id="3-2e"></td><td id="3-2f">Interest received</td><td id="3-2g">412.7</td><td id="3-2h">346.9</td></tr>
<tr><td id="3-2i"></td><td id="3-2j">Fixed deposits placed during the year</td><td id="3-2k">(11,500.0)</td><td id="3-2l">(10,402.8)</td></tr>
<tr><td id="3-2m"></td><td id="3-2n">Fixed deposits receipts during the year</td><td id="3-2o">11,051.0</td><td id="3-2p">10,354.5</td></tr>
<tr><td id="3-2q"></td><td id="3-2r">Net cash (used in)/generated from investing activities</td><td id="3-2s">(33.1)</td><td id="3-2t">331.3</td></tr>
</table>

<a id='6de6f7f0-11f9-43a4-bcf7-ba133ca0f4b5'></a>

NOVARTIS INDIA LIMITED Annual Report 2024–25

<a id='c10b5f03-64c7-4d4b-8a17-ee5d0e1b6e44'></a>

129

<!-- PAGE BREAK -->

<a id='55c9c235-7e74-4d1e-8f98-9efedca556fb'></a>

Statement of Cash Flows for the Year ended 31st March, 2025

<a id='c2e9d15f-46fe-4d34-ac81-bcf2e6266581'></a>

<table id="4-1">
<tr><td id="4-2"></td><td id="4-3">Year ended 31st March, 2025</td><td id="4-4">Year ended 31st March, 2024</td></tr>
<tr><td id="4-5"></td><td id="4-6">(in ₹ million)</td><td id="4-7">(in ₹ million)</td></tr>
<tr><td id="4-8">C. Cash flow from financing activities</td><td id="4-9"></td><td id="4-a"></td></tr>
<tr><td id="4-b">Lease payments</td><td id="4-c">(24.1)</td><td id="4-d">(37.0)</td></tr>
<tr><td id="4-e">Finance cost paid</td><td id="4-f">(0.1)</td><td id="4-g">(0.1)</td></tr>
<tr><td id="4-h">Dividends paid</td><td id="4-i">(617.3)</td><td id="4-j">(1,172.8)</td></tr>
<tr><td id="4-k">Net cash (used in) financing activities</td><td id="4-l">(641.5)</td><td id="4-m">(1,209.9)</td></tr>
<tr><td id="4-n">Net Increase in Cash and Cash Equivalents</td><td id="4-o">71.1</td><td id="4-p">255.4</td></tr>
<tr><td id="4-q">Cash and Cash Equivalents - At the beginning of the year</td><td id="4-r">449.6</td><td id="4-s">194.2</td></tr>
<tr><td id="4-t">Cash and Cash Equivalents - At the end of the year [Refer Note 9(a)]*</td><td id="4-u">520.7</td><td id="4-v">449.6</td></tr>
</table>
* Cash & Cash Equivalents includes bank overdraft [Refer Note 9(a)]

<a id='d8403cae-0fa8-474a-b873-d6b67a6dc9af'></a>

Note:
Disclosure of changes in liabilities arising from investing and financing activities on account of non-cash
transactions
<table id="4-w">
<tr><td id="4-x" rowspan="2">Particulars</td><td id="4-y" rowspan="2">April 1, 2024</td><td id="4-z" rowspan="2">Cash flow</td><td id="4-A" colspan="2">Non-Cash Changes</td><td id="4-B" rowspan="2">March 31, 2025</td></tr>
<tr><td id="4-C">Addition/ deletion</td><td id="4-D">Interest expense/ income</td></tr>
<tr><td id="4-E">Lease Liabilities (Refer note 31)</td><td id="4-F">69.5</td><td id="4-G">(24.1)</td><td id="4-H">—</td><td id="4-I">5.2</td><td id="4-J">50.6</td></tr>
<tr><td id="4-K">Interest accrued on deposit not due</td><td id="4-L">—</td><td id="4-M">—</td><td id="4-N">—</td><td id="4-O">—</td><td id="4-P">—</td></tr>
</table>

<a id='6e6c4da4-ffc9-41cf-95ec-83b67ff2ff1c'></a>

<table id="4-Q">
<tr><td id="4-R" rowspan="2">Particulars</td><td id="4-S" rowspan="2">April 1, 2023</td><td id="4-T" rowspan="2">Cash flow</td><td id="4-U" colspan="2">Non-Cash Changes</td><td id="4-V" rowspan="2">March 31, 2024</td></tr>
<tr><td id="4-W">Addition</td><td id="4-X">Interest expense/ income</td></tr>
<tr><td id="4-Y">Lease Liabilities (Refer note 31)</td><td id="4-Z">215.1</td><td id="4-10">(37.0)</td><td id="4-11">(123.4)</td><td id="4-12">14.8</td><td id="4-13">69.5</td></tr>
<tr><td id="4-14">Interest accrued on deposit not due</td><td id="4-15">(76.2)</td><td id="4-16">—</td><td id="4-17">—</td><td id="4-18">76.2</td><td id="4-19">—</td></tr>
</table>

<a id='fa23ef92-105e-4d41-beff-93d6157cd4bc'></a>

The Company has elected to present cashflows from Operating activities using indirect method.

<a id='396ecfe1-12af-4cd3-802d-6ba3315b2de9'></a>

The above Statement of Cash Flows should be read in conjunction with the accompanying notes.

<a id='ceebd53f-54ee-4d4f-a35d-ae2d2e3c6e0c'></a>

As per our report of even date attached.

<a id='b49f1efb-d336-4cf0-9f87-20adbe24543c'></a>

For B S R & Co. LLP
Chartered Accountants
Firm's Registration Number - 101248W/W-100022

<a id='cd8272e1-ee95-4396-84c6-1657ded9f4de'></a>

Christopher Snook
Chairman
DIN: 00369790

<a id='9537d471-67c4-4661-a02f-1cd1c38bb024'></a>

**Shilpa Joshi**
*Whole time Director & Chief Financial Officer*
DIN: 09775615

<a id='02bc698d-47d9-4f3f-9e9f-94c4fae50407'></a>

**Maulik Jhaveri**
*Partner*
Membership no. 116008
Mumbai, 9 May, 2025

<a id='8ed0efc9-e6c2-46e8-9540-8832ae63d684'></a>

Chandni Maru
Company Secretary & Compliance Officer
Membership no. ACS 60291
Mumbai, 9 May, 2025

<a id='46cc6240-2754-4e81-bf01-403a8525d15f'></a>

130

<a id='00b5913a-0095-405e-a093-df33c48476cc'></a>

NOVARTIS INDIA LIMITED
Annual Report 2024–25

<a id='32d5ede2-3f60-4915-98c5-39b66557be82'></a>

For and on behalf of Novartis India Limited
CIN – L24200MH1947PLC006104